(PharmaNewsWire.Com, September 08, 2017 ) Asia is predicted to show the wealthy growth in the forecast period. Within the Asian region, western pacific region account for larger share of blindness due to DR when equated to South-East Asia. The major factor contributing to the increasing share of Diabetic Retinopathy among the growing economies are huge pool of patients and increasing support and funding given by the government.
Diabetic retinopathy is considered as a severe sight threatening problem that results due to chronic diabetes. The treatment for diabetic retinopathy may require intraocular injections, anti VEGF drugs, laser surgery or vitrectomy depending on the severity of the condition.
Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of global diabetic retinopathy drug market in coming years. Rising medical procedures due to high penetration of medical insurance and rising government initiatives for prevention of diabetes related risks is also believed to garner the growth of retinopathy drug market in future.
The Asia Pacific Diabetic Retinopathy Market has been segmented on the basis of indication into Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is further sub segmented as Mild, Moderate and Severe. Based on Treatment type the market is bifurcated into Anti-Vascular Endothelial Growth Factor (VEGF) drug, Intraocular Steroid Injection, Laser Surgery and Vitrectomy.
By end users division is among Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers. Non-proliferative retinopathy dominated the overall market size estimated to lead the market. Augmented occurrence of diabetes, lack of diagnosis at right time, and non-compliant retinal screening of diabetic patients are predictable to drive the growth of non-proliferative diabetic retinopathy market share. In addition, based on geography the Asia Pacific Diabetic Retinopathy Market is analysed under the regions of India. China, Japan, Australia and South Korea.
The Major companies in Diabetic Retinopathy treatment market are Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd, Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc. and Ampio Pharmaceuticals Inc.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
